Spondyloarthropathies News

Women with ankylosing spondylitis showed a reduced response to TNF inhibitors compared with men, according to findings published in the Journal of Rheumatology.

Few patients with inflammatory arthritis reported participating in a structured self-management care program, although many physicians reported providing self-management support within routine care, according to findings published in Arthritis Care and Research.

In a study of six TNF inhibitors, infliximab demonstrated early superiority in treating ankylosing spondylitis, but the benefit faded at 24 weeks, leaving little difference between any of the therapies, according to findings published in the Journal of Rheumatology.

Patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis share comparable disease burden and treatment patterns in clinical practice, according findings published in Arthritis Care and Research.

The risk for ankylosing spondylitis among patients increased more than 7-fold following the first episode of anterior uveitis, and more than 17-fold after the second, according to findings published in Arthritis Care and Research.

Spondylarthritis, also called spondyloarthritis or spondyloarthropathy, is a family of arthritic conditions that affect the spine and, in rare cases, joints in the arms and legs. Whereas other forms of arthritis involve the joints, spondylarthritis involves the enthesis or area where the ligaments and bones connect.

A type of inflammatory arthritis, ankylosing spondylitis primarily affects an individual’s back or spine. The condition causes inflammation of the vertebrae and can lead to severe and chronic pain and discomfort. The pain tends to start in the lower back or the buttocks and may move into the chest, upper spine and neck. Ankylosing spondylitis also impacts other joints including the hips, shoulders, ribs, feet and knees. The systemic disease may also affect various organs.

Patients with axial spondyloarthritis who received treatment with certolizumab pegol exhibited rapid decreases in spinal and sacroiliac-joint inflammation as observed using MRI throughout a 4-year, phase 3 study, according to findings published in the Annals of the Rheumatic Diseases.

Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis over a 3-year period, with no new safety signals, according to findings from an extension of the phase 3 MEASURE 1 trial, published in Clinical and Experimental Rheumatology.

Lateral projection spinal bone mineral density increased over a period of 5 years in multiple locations along the spine, among patients with ankylosing spondylitis, according to findings published in Arthritis Research and Therapy.